DUBLIN – Symphogen A/S and Baxalta Inc. jointly made a major statement of intent in immuno-oncology, with an alliance focused on up to six immune checkpoint targets, under which Symphogen is getting $175 million up front plus up to $1.6 billion more in option fees and milestone payments.